Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
82.44
+1.40 (+1.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
August 23, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today
August 23, 2024
Via
Benzinga
The Stock Market Isn't Rocking This Month But The S&P 500 Is Headed For Its Best August In 3 Years
August 23, 2024
Kellanova and Fortinet are leading the S&P 500's August performance.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Europe Approves Moderna's RSV Vaccine For Adults 60 And Over
August 23, 2024
Moderna secures European Commission approval for its mRNA RSV vaccine, mRESVIA, to protect adults 60+ from RSV-related respiratory disease. The approval follows positive EMA CHMP opinion, based on...
Via
Benzinga
Moderna to Host Investor Event - R&D Day and Business Updates
August 22, 2024
Via
ACCESSWIRE
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccine Targeting KP.2 Variant of SARS-CoV-2
August 21, 2024
Via
ACCESSWIRE
Moderna's Options: A Look at What the Big Money is Thinking
August 21, 2024
Via
Benzinga
Moderna Receives European Commission Approval for RSV Vaccine mRESVIA(R)
August 23, 2024
Via
ACCESSWIRE
Ministry of Health, Labour and Welfare in Japan Approves Partial Change Application for Moderna's COVID-19 mRNA Vaccine Targeting SARS-COV-2 Variant JN.1
August 22, 2024
Via
ACCESSWIRE
Nasdaq 100 Slumps 1.6% As Traders Turn Cautious Ahead Of Powell's Jackson Hole Address
August 22, 2024
The Nasdaq 100 fell 1.6% on Thursday as investors awaited Fed Chair Powell's Jackson Hole speech. Private sector data and tech stock declines added to bearish sentiment.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
FDA Approves Updated COVID Vaccines From Pfizer And Moderna, But Leaves Out Novavax's Shot
August 22, 2024
The FDA granted emergency use authorization for updated mRNA COVID-19 vaccines targeting the Omicron KP.2 strain, including new formulas from Moderna and Pfizer/BioNTech. These vaccines, designed to...
Via
Benzinga
Exposures
COVID-19
Product Safety
Demystifying Moderna: Insights From 11 Analyst Reviews
August 15, 2024
Via
Benzinga
Stocks Move Lower As Rate Cut Enthusiasm Fades
August 22, 2024
The enthusiasm that followed the release of the Federal Reserve's meeting minutes is already fading.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 21, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, PDD Holdings, Extreme Networks, and Sprinklr and Encourages Investors to Contact the Firm
August 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MNRA STOCK NEWS: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Moderna, Inc. Class Action
August 20, 2024
From
Robbins LLP
Via
GlobeNewswire
S&P 500, Nasdaq 100 Snap 8-Day Winning Streak: What Triggered Wall Street's Setback On Tuesday?
August 20, 2024
S&P 500 ended Tuesday's session with slight declines, halting its best winning streak since May 2024. Here's the latest.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
August 20, 2024
GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs.
Via
MarketBeat
Exposures
COVID-19
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
August 19, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
August 19, 2024
Its 12-month relative strength performance is impressive, but Novavax now faces resistance.
Via
Investor's Business Daily
Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
August 19, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
MODERNA, INC. (NASDAQ: MRNA) INVESTOR ALERT: Investors With Large Losses in Moderna, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
August 19, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
August 19, 2024
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
Via
Benzinga
Topics
ETFs
Exposures
COVID-19
Product Safety
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
August 19, 2024
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19.
Via
The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna and Sprinklr and Encourages Investors to Contact the Firm
August 18, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
MRNA Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Filed Against Moderna, Inc.
August 18, 2024
From
Robbins LLP
Via
Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
August 16, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
August 16, 2024
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve...
Via
Benzinga
Exposures
COVID-19
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
August 15, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.